Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
News|Articles|November 24, 2021
- Pharmaceutical Technology's In the Lab eNewsletter, December 2021
- Volume 16
- Issue 12
MilliporeSigma Unveils ColorWheel Flow Cytometry Portfolio
Author(s)Pharmaceutical Technology Editors
MilliporeSigma’s new ColorWheel flow cytometry portfolio is designed to create antibodies and dyes analogous to a primary conjugated antibody.
Advertisement
MilliporeSigma announced the launch of its new ColorWheel flow cytometry portfolio on Nov. 16, 2021. The ColorWheel uses technology optimized for flow cytometry that allows users to select antibodies and dyes for assembly in any desired combination, resulting in an output of mix-and-match antibodies and dyes analogous to a primary conjugated antibody.
According to a company press release, multiplexing in flow cytometry can be difficult because researchers must consider instrument configuration, antigen expression and dye brightness balance, and antibody–dye combination availability. In this regard, the ColorWheel is designed to overcome these constraints by making it easier to build a new multiplex assay for samples with varying expression levels of antigen.
According to the press release, the ColorWheel:
- Has the flexibility to pair any antibody with any dye in a ready-to-use, convenient format
- Can be used in five minutes of hands-on time, minimizing necessary time and effort
- Uses a preservative-free presentation that promotes sustainability and wider sample type compatibility
- Delivers a lyophilized product, enhancing stability and allowing for ambient shipping.
Source:
Articles in this issue
almost 5 years ago
Contamination Control for Cell and Gene Therapies Needs New Analyticsalmost 5 years ago
New Carbon Nanotube-Based Sensor Can Detect SARS-CoV-2 Proteinsalmost 5 years ago
Lonza Invests in Microbial Development Lab Expansionalmost 5 years ago
Synthace Raises $35 Million to Expand Access to R&D Technologyalmost 5 years ago
Fujifilm Irvine Scientific Expands Cell Culture R&D Centeralmost 5 years ago
Element Acquires JMI Laboratoriesalmost 5 years ago
GenScript Opens New Gene Synthesis Center in New Jerseyalmost 5 years ago
Gentronix Expands Lab Facilities, Increases Testing CapacityAdvertisement
Related to this article
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Advertisement
Advertisement